These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 34002069

  • 1. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD, Klaassen Z, Saad F.
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [Abstract] [Full Text] [Related]

  • 2. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U, Agarwal N.
    Cancer Treat Res Commun; 2020 Jul; 25():100205. PubMed ID: 32822968
    [Abstract] [Full Text] [Related]

  • 3. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.
    Curr Treat Options Oncol; 2019 Feb 11; 20(2):14. PubMed ID: 30741354
    [Abstract] [Full Text] [Related]

  • 4. M0CRPC overview of management options.
    Hess-Busch Y, Hadaschik B, Hess J.
    World J Urol; 2021 Feb 11; 39(2):349-356. PubMed ID: 31691081
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov 11; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

  • 8. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 11; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, Bazargani S, Costa J, Bandyk M, Ganapathi HP, Koochekpour S, Balaji KC.
    Urol Oncol; 2020 Nov 11; 38(11):826-834. PubMed ID: 32605736
    [Abstract] [Full Text] [Related]

  • 11. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR.
    Adv Ther; 2022 Nov 11; 39(11):5025-5042. PubMed ID: 36028656
    [Abstract] [Full Text] [Related]

  • 12. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 11; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
    Mori K, Kimura T, Fukuokaya W, Iwatani K, Sakanaka K, Kurokawa G, Yanagisawa T, Sasaki H, Miki J, Shimomura T, Miki K, Hatano T, Endo K, Egawa S.
    Int J Clin Oncol; 2020 Mar 11; 25(3):479-485. PubMed ID: 31512007
    [Abstract] [Full Text] [Related]

  • 16. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI.
    Prostate Cancer Prostatic Dis; 2022 Feb 11; 25(2):139-148. PubMed ID: 34054128
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.